CD19 on IgD+ CD38- naive (B cell group) (OR, 0.969; 95% CI, 0.954–0.985; P < 0.001; PFDR = 0.021) decreased RA risk (Supplementary Figure S3). This evidence concerns the gene CD19 and rheumatoid arthritis.